https://www.selleckchem.com/pr....oducts/salinomycin.h
6 years; 101 (99%) had received at least one anti-TNF. The median follow-up time was 52 weeks. Sixty-eight per cent of patients discontinued therapy after a median time of 33 weeks. Vedolizumab success was reached in 23/102 (22.5%). Among patients with setons at initiation, 9/61(15%) had a successful removal. In multivariable analysis, factors associated with success were the number of prior biologic agents (≥3, odds ratio, OR 0.20, 95% CI 0.04-0.98) and no antibiotics at initiation (OR 4.76, 95% CI 1.25-18.19). In 49 patients with